SBIR/STTR Research Award

Effect of flow lamination device on aerosolized drug delivery characteristics

Award identifier a9ff99bafce5a051ce0639237f7d3c11b437c1a71a28cfaf3ff0edeb8411ebf5Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$259,602

Program and phase

SBIR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SkinAxis LLC
Proposal award date
2022-09-10
Contract end date
2023-08-31
UEI
WR1FPNGBQ4W9
Solicitation number
PA21-259
Topic code
NHLBI

Research abstract

The respiratory tract is one of the most attractive pathways for delivering aerosolized medications both to the lungs and to systemic circulation. It is the fastest, it's devoid of drug efflux transporters and metabolizing enzymes, it has a huge alveolar surface area (700 square feet) and a very thin mucosal barrier at alveolar level (0.1 mm), and it is perfused by 100% of cardiac output unlike any other organ or system. However there are serious challenges to efficient delivery to the lower lungs and to taking advantage of the large alveolar surface area. Up to 80% of the medication may be deposited in the upper airways, most of it in the oropharyngeal area, causing side effects and waste, and making the delivery to target areas unpredictable, inefficient, and even unreliable. Therefore overcoming the upper airway barriers such as oropharynx is important for more efficient drug delivery to the lower lungs. Among many factors involved in this process, Inertial Impaction, Turbulent Mixing and Interception are especially significant in upper airways. And a single factor that can have an impact on all 3 of them is the turbulence in the outflow of the aerosol delivery device, which has not been studied sufficiently as an independent factor. In our previous study ModiFlow has been shown to reduce turbulence in the incoming flow, and to improve the efficiency of aerosol delivery to distant targets. The objectives of the proposed study are to test the ability of ModiFlow to improve the delivery of aerosolized drugs across a spatial Barrier Imitation of the oropharynx. Objective 1: To test the ability of laminated flow from ModiFlow to improve the delivery of aerosolized Fluticasone to 3D mucosal tissue models placed within a Barrier Imitation. Objective 2: To manipulate the ModiFlow geometry to achieve the best aerosol flow characteristics at the exit of the Barrier Imitation. The Barrier Imitation is designed to mimic two main characteristics of the oropharyngeal barrier in the airways – narrowing and curving. By strategically placing 3D mucosal tissue models at the point of narrowing and at the end of curving, and by measuring the medication deposition on them, we'll be able to draw conclusions about the effects of flow lamination on overcoming these types of barriers. At the same time, detailed characterization of aerosol outflow from the distal end of the Barrier Imitation will pour light on the effects of ModiFlow geometry on it, providing valuable information for improving those effects. The outcomes of the proposed study will help better understand the effects of turbulence in the device outflow on the efficiency of aerosol delivery across upper airway barriers to the lower lungs.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2017–2022). Reported award amounts total $559,277. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.